Scientists at the University of Oxford have started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.
The goal of the trial is to evaluate the safety, tolerability and immunogenicity of the HIVconsvX vaccine -- a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.
Thirteen healthy, HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks.
"An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure," said lead researcher Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute at Oxford, in a statement.
While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system's potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV -- an "Achilles heel" common to most HIV variants.
"Achieving protection against HIV is extremely challenging and it is important that we harness the protective potential of both the antibody and T cell arms of the immune system," said Paola Cicconi, Senior Clinical Research Fellow at the Jenner Institute.
At present, prevention of HIV largely focuses on behavioural and biomedical interventions such as voluntary medical male circumcision, condom use, and anti-retroviral drugs used prior to exposure.
The researchers aim to report results of the trial by April 2022. Similar trials are also planned in Europe, Africa and the US.
Govt slashes prices of 41 medicines
Antacids, multivitamins, and antibiotics are among the medicines that will become cheaper, according to a notification issued by the Department of Pharmaceuticals and National Pharmaceutical Pricing Authority (NPPA).
At least 1 in 5 new mothers experiences postpartum depression: Doctors
While parenthood comes as a blessing for many, for more than 20 per cent of mothers, the new chapter of life creates stress, anxiety and postpartum depression, which can turn fatal for both the mother and child, without adequate support, said doctors on Mother’s Day on Sunday.
New immunotherapy to fight cancer, keep healthy cells safe
A team of US researchers has developed a new immunotherapy technique that uses cytokine proteins as a potential treatment, effectively targeting tumours without causing harm to healthy cells.
Why excess sugar, oil are as dangerous for liver as alcohol
While alcohol is known to be bad for liver health, consuming foods rich in sugar and oil may be equally dangerous for the organ as well as for overall health, said doctors on Thursday, ahead of World Liver Day.
Lungs of young adults more susceptible to SARS-CoV-2 virus: Study
While older age has been associated with an increased risk of SARS-CoV-2, the virus responsible for Covid-19, a new study has revealed that the lungs of young adults are more susceptible to the virus.
Congress in Tripura blocks rail stations to protest police fired-killing of 5 farmers in MP
The firing on Tuesday came during raucous protests to demand better crop prices in the drought-ravaged region that saw one farmer suicide every five hours in the past two years.
DMs, SPs of violence-hit MP districts transferred
The farmers agitation entered its eighth day on Thursday. The peasants have been on strike since June 1, demanding loan waiver and fair price for their produce.
Indian American selected among 12 NASA astronaut candidates
He continued on to earn a master's degree in aeronautics and astronautics from Massachusetts Institute of Technology and graduated from the US Naval Test Pilot School.